AMPHASTAR PHARMACEUTICALS IN (AMPH)
US03209R1032 - Common Stock
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.
Bullish Two Hundred Day Moving Average Cross - AMPH
Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Beats Revenue for Q2 2024
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amphastar Pharma (NASDAQ:AMPH) just reported results for the second quarter of ...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024
Amphastar Pharmaceuticals Enters Oversold Territory (AMPH)
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
BetterInvesting™ Magazine Update on Amphastar Pharmaceuticals Inc. and Medtronic PLC
/PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Amphastar Pharmaceuticals Inc. (NASDAQ:...
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amphastar Pharma (NASDAQ:AMPH) just reported results for the first quarter of 2...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024
Oversold Conditions For Amphastar Pharmaceuticals (AMPH)
Commit To Buy Amphastar Pharmaceuticals At $22.50, Earn 18.5% Annualized Using Options
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference
Amphastar Pharmaceuticals Becomes Oversold (AMPH)
Amphastar Pharmaceuticals (AMPH) Shares Cross Below 200 DMA
Amphastar Pharmaceuticals Non-GAAP EPS of $0.88 misses by $0.03, revenue of $178.1M beats by $4.77M (NASDAQ:AMPH)
Amphastar Pharmaceuticals reports Q4 financial results with a Non-GAAP EPS of $0.88, missing estimates by $0.03, while revenue of $178.1M beats expectations...
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.